CareDx

CareDx, Inc. is a molecular diagnostics company specializing in transplant surveillance, specialty oncology, and cell therapy testing. The company's AlloSure Kidney donor-derived cell-free DNA test is the leading non-invasive transplant monitoring assay in U.S. clinical use, complemented by AlloMap Heart for heart transplant recipients and HeartCare for combined heart transplant surveillance. Following the July 2026 close of the Naveris acquisition (adding the Medicare-covered NavDx MRD blood test for HPV-positive head-and-neck and anal cancers) and the $171.2M divestiture of its global Lab Products business to Eurobio Scientific, CareDx is repositioned as a focused U.S. precision-medicine testing and digital-patient-solutions company.